Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2016

01-12-2016 | Brief Article

Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans

Authors: Jae Yong Choi, Chul Hyoung Lyoo, Jin Su Kim, Kyeong Min Kim, Minkyung Lee, Young Hoon Ryu

Published in: Molecular Imaging and Biology | Issue 6/2016

Login to get access

Abstract

Purpose

[18F]Mefway is a positron emission tomography (PET) radioligand for quantification of the brain serotonin 1A (5-HT1A) receptor density. The purpose of this study was to evaluate the radiation safety of [18F]Mefway in humans.

Procedures

Six healthy volunteers (three males and three females) were whole-body PET scanned for 114 min after injection of [18F]Mefway (226 ± 35 MBq). Estimated radiation doses were determined by the OLINDA/EXM software.

Results

[18F]Mefway was safe and well tolerated by all subjects. Residence time ranges from 0 (gallbladder) to 0.822 h (urinary bladder wall). While the estimated radiation doses in the reproductive and blood-forming organs were below 13.35–22.87 μSv/MBq, radiation dose in the urinary bladder wall was 471 μSv/MBq. The mean effective dose was 40.23 ± 6.63 μSv/MBq.

Conclusion

For a typical single injection of 185 MBq (5 mCi), the dose will result in 87.1 mSv for the urinary bladder wall. To reduce radiation burden, the bladder voiding can be used before [18F]Mefway PET scan.
Literature
1.
Lai MK, Tsang SW, Francis PT et al (2003) Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 974:82–87CrossRefPubMed
2.
Drevets WC, Frank E, Price JC et al (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375–1387CrossRefPubMed
3.
Kepe V, Barrio JR, Huang SC et al (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci U S A 103:702–707CrossRefPubMedPubMedCentral
4.
Kish SJ, Tong J, Hornykiewicz O et al (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131PubMed
5.
Carson RE, Lang L, Watabe H et al (2000) PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol 27:493–497CrossRefPubMed
6.
Gunn RN, Sargent PA, Bench CJ et al (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426–440CrossRefPubMed
7.
Lacan G, Plenevaux A, Rubins DJ et al (2008) Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 35:2256–2266CrossRefPubMed
8.
Mukherjee J, Bajwa AK, Wooten DW et al (2015) Comparative assessment of F-Mefway as a serotonin 5-HT receptor PET imaging agent across species- rodents, nonhuman primates, and humans. J Comp Neurol 524:1457–1471CrossRefPubMed
9.
Saigal N, Pichika R, Easwaramoorthy B et al (2006) Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med 47:1697–1706PubMed
10.
Choi JY, Shin S, Lee M et al (2014) Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus. Synapse 68:363–368CrossRefPubMed
11.
Lee M, Ryu YH, Cho WG et al (2014) Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[18F]Mefway. Appl Radiat Isot 94:30–34CrossRefPubMed
12.
13.
Hillmer AT, Wooten DW, Bajwa AK et al (2014) First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. J Nucl Med 55:1973–1979CrossRefPubMedPubMedCentral
14.
Shoup TM, Yokell DL, Rice PA et al (2013) A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Label Compd Radiopharm 56:736–740CrossRef
15.
Hines CS, Liow JS, Zanotti-Fregonara P et al (2011) Human biodistribution and dosimetry of 11C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 6:e25309CrossRefPubMedPubMedCentral
16.
Zanotti-Fregonara P, Lammertsma AA, Innis RB (2013) Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 40:1781–1783CrossRefPubMed
17.
Constantinescu CC, Sevrioukov E, Garcia A et al (2013) Evaluation of [18F]Mefway biodistribution and dosimetry based on whole-body PET imaging of mice. Mol Imaging Biol 15:222–229CrossRefPubMed
18.
Parsey RV, Belanger MJ, Sullivan GM et al (2005) Biodistribution and radiation dosimetry of 11C-WAY100,635 in humans. J Nucl Med 46:614–619PubMed
19.
Anjos DA, Etchebehere EC, Ramos CD et al (2007) 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48:764–770CrossRefPubMed
20.
Diehl M, Manolopoulou M, Risse J et al (2004) Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide. Acta Med Austriaca 31:76–78PubMed
21.
Koyama K, Okamura T, Kawabe J et al (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353–358PubMed
22.
Miraldi F, Vesselle H, Faulhaber PF et al (1998) Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23:3–7CrossRefPubMed
Metadata
Title
Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans
Authors
Jae Yong Choi
Chul Hyoung Lyoo
Jin Su Kim
Kyeong Min Kim
Minkyung Lee
Young Hoon Ryu
Publication date
01-12-2016
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2016
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-016-0955-8

Other articles of this Issue 6/2016

Molecular Imaging and Biology 6/2016 Go to the issue

Research Article

In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody

Research Article

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Research Article

Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population

Research Article

A Clinical Wide-Field Fluorescence Endoscopic Device for Molecular Imaging Demonstrating Cathepsin Protease Activity in Colon Cancer

Research Article

Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using 99mTc-Modified Nanobodies and SPECT/CT

Research Article

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography